New cancer drug trial seeks to control advanced tumors
Disease control
Recruiting now
This early-stage study is testing a new drug called TRK-950 in people with advanced solid tumors that have not responded to standard treatments. The trial has three parts: testing TRK-950 alone, testing it combined with an existing immunotherapy (nivolumab), and specifically test…
Phase: PHASE1, PHASE2 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC